Valye reports for unlimited access

Alaunos Therapeutics, Inc. is a clinical-stage biotechnology company incorporated in Delaware, headquartered in Fort Lauderdale, Florida, and listed on the Nasdaq Capital Market under the ticker TCRT. The company is focused on discovering and developing novel, orally administered therapeutics targeting obesity and related metabolic disorders through a non-hormonal mechanism of action. The company has identified a lead compound that has demonstrated proof-of-concept in preclinical pharmacology studies using a diet-induced obesity mouse model, showing statistically significant reductions in body weight and favorable metabolic changes. The company plans to advance this candidate into investigational new drug (IND)-enabling studies, contingent on securing additional capital and favorable data. As of December 31, 2025, the company reported cash and cash equivalents of approximately $1.385 million and a net loss of $4.176 million for the fiscal year. The company’s stockholders’ equity was approximately $2.153 million, below Nasdaq’s minimum continued listing requirement, resulting in a notice of non-compliance and a requirement to submit a compliance plan. The company’s board comprises four directors with financial and industry expertise, including CEO Holger Weis. The company has recently wound down its sole clinical study, which impacted its stock price. It is actively exploring strategic financing and collaboration opportunities to support its development programs and operations.

Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company incorporated in Delaware and headquartered in Vero Beach, Florida. The company is engaged in the research and development of pharmaceutical products, with a focus on next-generation cancer therapies and treatments for gastrointestinal disorders such as gastroparesis. Processa's pipeline includes NGC-Cap, a candidate showing promising clinical data in breast cancer studies, and PCS12852, licensed exclusively from Intact Therapeutics for gastroparesis treatment. The company actively participates in industry conferences and investor events to showcase its development progress. Leadership includes CEO George Ng and Chief Development and Regulatory Officer Dr. Sian Bigora, who transitioned to part-time status in 2026. Financially, Processa reported a net loss of $13.56 million for the fiscal year ended December 31, 2025, with cash and equivalents of approximately $5.54 million and a current ratio of 2.54, reflecting adequate liquidity. The company is exploring a cryptocurrency treasury strategy initiated in 2025, which adds complexity and regulatory considerations to its financial management.

Tesla, Inc. is a leading manufacturer of electric vehicles and related products, operating within the Consumer Cyclical sector and Auto Manufacturers industry. The company is headquartered in Austin, Texas, and has a well-established governance structure with Elon Musk as CEO and a diverse board of directors. Tesla's business model focuses on sustainable transportation solutions, including electric vehicles, energy products, and software services. The company reports detailed financial results quarterly and annually, with recent filings showing significant revenue and positive net income. Tesla maintains a strong liquidity position with substantial cash reserves and current assets exceeding current liabilities. The company also has performance-based executive compensation tied to operational and market milestones. Tesla faces various risks as disclosed in its SEC filings, which could impact its business and financial outcomes.

MODIV INDUSTRIAL, INC. operates as a real estate investment company with publicly traded Class C common stock and Series A preferred stock on the New York Stock Exchange. The company reported $46.4 million in revenue and $1.07 million in net income for the fiscal year ended December 31, 2025. It maintains liquidity with $14.4 million in cash and equivalents and has extended its credit facility maturity to July 2028. The company pays monthly dividends on common stock and has a board of directors with extensive real estate and financial expertise. Recent quarterly earnings reports and business updates have been regularly disclosed through SEC filings and news releases.

Coursera, Inc. is a publicly traded Delaware corporation headquartered in Mountain View, California, operating an online education platform. The platform offers a broad portfolio of educational content and credentialing programs developed in collaboration with content creators such as universities and other institutions. Revenue is generated through consumer subscriptions, enterprise subscriptions, and degree programs, with content costs paid based on learner engagement. The company maintains strong liquidity with cash and equivalents of approximately $789.8 million as of March 31, 2026. Coursera's board includes co-founder Andrew Y. Ng and President and CEO Gregory M. Hart. The company is currently pursuing a merger with Udemy, which is subject to various conditions and risks. Coursera faces a competitive and evolving market landscape, regulatory and operational risks, and challenges related to growth and profitability [S1][S2].

BiomX Inc. is a company listed on the NYSE American exchange under the ticker PHGE. The company has undergone recent leadership changes with Michael Oster appointed CEO in March 2026 and David Rokach appointed CFO in February 2026. The Board consists of four members, with three independent directors. BiomX has expanded its business focus into the defense sector through acquisitions of Zorro Net Ltd. and DR. Frucht Systems Ltd. (DFSL) in April 2026. These acquisitions involved a combination of stock issuance, promissory notes, warrants, and performance-based earnouts. The company has ongoing clinical development programs, including studies related to cystic fibrosis, with some trials halted due to adverse events and others continuing with revised dosing. Financially, as of December 31, 2025, BiomX reported a net loss of $36.2 million, cash and equivalents of $4.36 million, and a current ratio of 0.87, indicating liquidity challenges. The company has a Code of Business Conduct and Ethics and established governance committees composed of independent directors. Major shareholders include Water IO Ltd. and Mandragola Ltd., with related party transactions disclosed.

New Fortress Energy Inc. operates in the energy sector with a focus on liquefied natural gas (LNG) infrastructure and related services. The company is led by founder and CEO Wesley R. Edens and governed by a board with extensive financial and industry expertise. The company reported approximately $1.5 billion in revenue for fiscal year 2025 but recorded negative earnings per share of $6.63. Liquidity metrics as of the end of 2025 show a low current ratio of 0.15 and cash ratio of 0.03, indicating a liquidity challenge relative to current liabilities. The company is actively engaged in a financial restructuring process involving amendments to credit agreements, forbearance arrangements, and new term loan facilities, including a $50 million Brazil Bridge Term Loan Facility for its Brazilian subsidiary. The restructuring aims to address the company's funded debt obligations and improve financial flexibility. The company has disclosed material weaknesses in internal controls over financial reporting and is undertaking restatement and remediation efforts. Recent earnings calls and news coverage provide insights into operational and financial developments.

Green Dot Corporation is a financial services company specializing in prepaid and debit card products and banking-as-a-service (BaaS) offerings. The company generates a majority of its operating revenues from a single BaaS partner and retail sales through Walmart, which are critical to its business model. It also provides tax refund processing services through a concentrated base of tax preparation partners. The company’s operations are seasonal, with higher activity in the first half of the year due to tax refund cycles. Green Dot faces intense competition from larger financial institutions and fintech companies, including digital-first platforms offering low-cost alternatives. The company relies on third-party vendors for key operational functions and has relocated significant software development from China to other locations. Financially, Green Dot reported revenues of approximately $2.08 billion and a net loss of $98.9 million for the fiscal year ended December 31, 2025, with liquidity ratios indicating current liabilities exceed current assets. The company has increased debt obligations through senior unsecured notes issued in 2024 and 2025. The Board of Directors includes seasoned executives with expertise in financial services, payments, and technology.

Spirit Aviation Holdings, Inc. is a Delaware-based holding company formed as part of a corporate reorganization following Spirit Airlines' initial Chapter 11 bankruptcy filing in November 2024. Spirit Airlines operates as a wholly owned subsidiary. The company filed for Chapter 11 bankruptcy again on August 29, 2025, with cases jointly administered in the Southern District of New York. The company is currently engaged in restructuring efforts, including renegotiations of aircraft engine support agreements and settlements with creditors. The management team comprises experienced aviation and restructuring professionals. The company is in the process of an orderly wind-down of operations amid financial pressures, with ongoing court proceedings and creditor negotiations shaping its restructuring path.

Scienture Holdings, Inc. is a specialty pharmaceutical company that acquired Scienture LLC in 2024. Scienture LLC focuses on developing and commercializing products for cardiovascular and central nervous system diseases. The company launched ARBLI™, the first FDA-approved ready-to-use oral liquid formulation of losartan for hypertension, in Q3 2025. It is preparing to launch REZENOPY™, a naloxone nasal spray for opioid overdose treatment, with commercialization efforts underway. The product pipeline includes novel candidates targeting migraine, thrombosis, pain, and related disorders. The company has divested non-core subsidiaries to focus on branded and specialty pharmaceutical operations. Revenue recognition is primarily from wholesale distributors, with revenues increasing significantly in 2025 due to ARBLI™ sales. The company has raised capital through equity offerings and secured promissory notes to support commercialization and pipeline development. Leadership changes and Nasdaq compliance issues have been addressed recently. The company faces risks related to regulatory agency disruptions and funding availability.

Super League Enterprise, Inc. operates in the emerging playable media sector, providing interactive advertising and gaming-related content solutions. The company is headquartered in Santa Monica, California, and trades on the Nasdaq Capital Market under the ticker SLE. Leadership includes CEO Matthew Edelman, who has driven significant revenue growth and multiple acquisitions since joining the company. The company has focused on expanding its platform through acquisitions such as Let's Bounce and the Misfits Ads Division, aiming to boost in-game marketing and measurement capabilities. Financially, the company reported a net loss of $20.7 million for the fiscal year ended December 31, 2025, with a strong liquidity position supported by $14.4 million in cash and equivalents and a current ratio of 4.36. Recent quarterly results have shown losses and revenue shortfalls, reflecting challenges in scaling revenue. The company continues to pursue strategic growth initiatives and capital management to support its business model [S1][N1][N3][N7].

Tevogen Bio Holdings Inc. is a Delaware-based clinical-stage biotechnology company focused on developing immunotherapy treatments, including its lead candidate TVGN 489 and other products developed with its proprietary ExacTcell technology. The company integrates artificial intelligence through its Tevogen.AI initiative to accelerate clinical trial participation and enhance drug discovery, exemplified by the PredicTcell model nearing completion. Tevogen has expanded its headquarters to support growth in AI and biosimilars, funded in part by the CEO's personal contribution. The company is listed on Nasdaq and recently completed a 1-for-50 reverse stock split to address minimum bid price compliance. Financially, Tevogen reported a net loss of $26.3 million for the fiscal year ended December 31, 2025, with no cash on hand and a current ratio of 0.22, reflecting liquidity constraints. The company requires substantial additional financing to continue operations and development programs. Its board comprises experienced directors with expertise in healthcare, risk management, and human resources, and the executive team includes CEO Dr. Ryan Saadi and CFO Kirti Desai [S1][S2][N1][N6][N8].

VolitionRx Limited is a biotechnology company developing diagnostic assays for cancer detection. The company operates through multiple subsidiaries globally and focuses on innovative technologies such as Capture-Seq and the Nu.Q cancer assay program. It aims to provide early-stage cancer detection solutions and has engaged in strategic partnerships to commercialize its products. The company is publicly traded on the NYSE American exchange under the ticker VNRX and has recently undergone a one-for-twenty reverse stock split. Financially, the company reported modest revenue and significant net losses for the fiscal year ended December 31, 2025, with liquidity challenges indicated by low current and cash ratios. The board comprises experienced professionals with expertise in biotechnology, diagnostics, and business development.

ACRES Commercial Realty Corp. operates as a real estate finance company primarily engaged in originating, holding, and managing commercial real estate mortgage loans. It may also hold equity investments in commercial real estate properties through direct ownership and joint ventures. The company is externally managed by ACRES Capital Corp. and its subsidiaries, with executive officers employed by the Manager. ACRES is listed on the New York Stock Exchange with common stock and preferred stock series. The company is in the process of internalizing management by acquiring its Manager, which will terminate the existing external management agreement and make ACRES internally managed. The Board of Directors comprises experienced professionals with backgrounds in real estate finance, investment, law, and governance. ACRES maintains a code of ethics, robust cybersecurity and business continuity programs, and conducts anti-corruption and due diligence reviews on counterparties. The company reimburses its Manager for certain employee costs and has a compensation program involving equity incentives. Financially, ACRES reported $79.95 million in revenue and $27.98 million in net income for fiscal year 2025, with $83.77 million in cash and equivalents at year-end. Recent activities include pricing a $1.0 billion CLO backed by commercial mortgage loans and quarterly earnings disclosures through Q1 2026.

Soleno Therapeutics, Inc. is a Delaware-based biopharmaceutical company focused on developing and commercializing therapies for rare diseases. The company operates with a leadership team experienced in pharmaceutical development, commercialization, and finance. Soleno's product portfolio includes VYKATTM XR (diazoxide choline), a commercial product targeting rare disease indications. The company reported profitability in 2025 with net income of $20.89 million and maintains a strong liquidity position with over $70 million in cash and $235 million in short-term investments as of December 31, 2025. In April 2026, Soleno agreed to be acquired by Neurocrine Biosciences in a cash transaction, subject to regulatory approvals and tender offer conditions. The company has a board of directors with expertise in biopharmaceuticals, clinical development, and corporate governance. Recent corporate developments include the appointment of a new CFO and ongoing clinical and regulatory activities.

Owlet, Inc. is a publicly traded company incorporated in Delaware and headquartered in Lehi, Utah. The company operates in the healthcare technology sector, focusing on products sourced primarily from Southeast Asia, including Thailand and Vietnam. Owlet has experienced recurring operating losses and negative cash flows since inception, financing operations mainly through equity raises and borrowings. The company faces challenges from tariffs imposed on its imported products, which have increased costs and affected profitability. Leadership includes CEO Kurt Workman, who has a long history with the company, including co-founding it. The board comprises experienced professionals from healthcare, technology, and finance sectors. Owlet's financial position as of the end of 2025 shows a moderate liquidity position but ongoing losses and capital needs raise concerns about its going concern status.

Vaxart, Inc. focuses on developing oral recombinant protein vaccines using its proprietary platform. The company operates primarily in one segment and is headquartered in South San Francisco, California. Its business model relies on government contracts, notably with HHS BARDA, and collaborations such as the licensing agreement with Dynavax for its oral COVID-19 vaccine candidate. Vaxart finances its operations through equity offerings, government funding, and licensing revenues. The company reported $237.3 million in revenue and $16.3 million in net income for the fiscal year ending December 31, 2025. Research and development expenses are significant, reflecting ongoing clinical programs. Liquidity metrics as of year-end 2025 show a current ratio of 1.57 and cash ratio of 0.47, indicating moderate liquidity to support operations.

Traws Pharma, Inc. operates as a clinical-stage biopharmaceutical company developing antiviral therapies primarily for infectious diseases such as COVID-19 and influenza. Its pipeline includes Ratutrelvir, which has completed Phase 2 enrollment, and Tivoxavir Marboxil, for which IND filings have been made. The company has expanded its TXM program to include influenza indications. Traws Pharma is publicly traded on Nasdaq and maintains active regulatory engagement, including FDA briefing document submissions. The company has secured significant financing to support its development programs and reported positive clinical data in recent periods. Its leadership team comprises experienced executives with backgrounds in pharmaceutical development and finance.

KalVista Pharmaceuticals, Inc. is a Delaware-based pharmaceutical company specializing in treatments for hereditary angioedema (HAE). Its lead product, EKTERLY, has received clinical and regulatory recognition, including recommendation as a first-line treatment in pediatric HAE guidelines. The company reported revenues of $13.7 million for Q3 2025 and a net loss of $109.5 million for the fiscal year 2025, reflecting ongoing investment in clinical development and commercialization. KalVista maintains a strong liquidity position with over $229 million in cash and equivalents as of year-end 2025. In April 2026, KalVista entered into a merger agreement with Chiesi Farmaceutici S.p.A., which includes a tender offer to acquire all outstanding shares. The company is advancing clinical trials, including KONFIDENT-S and KONFIDENT-KID, and pursuing international expansion and strategic partnerships.

Whitestone REIT operates as a real estate investment trust with a focus on retail and commercial properties. The company is headquartered in Houston, Texas, and is listed on the NYSE under the ticker WSR. Whitestone maintains a $375 million unsecured revolving credit facility and a $375 million unsecured term loan, providing liquidity and capital resources for operations and growth. The company has a seasoned management team and Board of Trustees with extensive experience in real estate finance and operations. Whitestone has recently engaged in strategic initiatives including dividend increases, share repurchases, and is currently subject to a proposed acquisition by Ares Management. The company emphasizes performance-based executive compensation aligned with shareholder interests.

LivePerson, Inc. operates a digital customer conversation platform that enables brands to engage consumers through AI-powered conversations across multiple digital channels including mobile apps, web browsers, SMS, social media, and third-party messaging platforms. The platform integrates voice and digital channels and supports a collaborative interaction model involving humans, proprietary AI, third-party bots, and large language models. The company generates revenue primarily from hosted services subscriptions and professional services. It operates globally with significant revenue from the Americas, EMEA, and APAC regions. LivePerson’s business model includes long-term subscription contracts with revenue recognized ratably over the contract term. The company has undergone a reverse stock split to maintain Nasdaq listing compliance and reports ongoing net losses while investing in platform development and AI capabilities.

CERo Therapeutics Holdings, Inc. is a Delaware-based emerging growth biopharmaceutical company specializing in immunotherapy drug development. Its lead product candidate, CER-1236, targets acute myeloid leukemia and has progressed through Phase 1 clinical trials with favorable safety data. The company has secured FDA Fast Track and Orphan Drug designations for CER-1236, underscoring regulatory recognition of its potential therapeutic value. CERo holds a portfolio of 18 patents and applications expanding its immunotherapy pipeline. Financially, the company reported a net loss of nearly $20 million for the fiscal year ended 2025, with limited liquidity and a current ratio of 0.3 as of year-end 2025. CERo was delisted from Nasdaq in October 2025 but has taken steps to regain compliance through capital raises and convertible notes. The leadership team and board bring extensive experience in biotechnology, venture capital, and pharmaceutical development.

AMC ENTERTAINMENT HOLDINGS INC is a Delaware-incorporated company operating in the entertainment industry, primarily focused on motion picture exhibition. The company licenses first-run motion pictures from major studios and operates a network of theatres with various premium formats and amenities. AMC's business is seasonal, with peak attendance during summer and holiday periods. The company has implemented loyalty programs and promotional pricing to enhance customer engagement. AMC has undertaken refinancing transactions to extend debt maturities and improve liquidity, including a recent $425 million credit facility for its subsidiary Odeon Cinemas Group Limited. The company faces risks from competition, changes in theatrical release windows, labor disruptions in film production, and market volatility influenced by retail investor trading dynamics.

Oportun Financial Corp is a mission-driven financial services company that offers unsecured and secured personal loans, automated savings products, and Lending as a Service partnerships. Its products are designed to serve underserved consumers in the U.S., helping them build financial health through responsible credit and savings solutions. The company operates through digital channels, retail locations, and partner networks. It relies on a bank partner, Pathward, for the majority of loan originations and funds its loan portfolio through capital markets transactions including asset-backed securities. Oportun reported fiscal year 2025 revenue of approximately $956.7 million and net income of $25.2 million. The company faces risks related to competition, credit market disruptions, regulatory compliance, and operational dependencies.

Fossil Group, Inc. operates as a consumer retail company primarily focused on watches and accessories. The company is incorporated in Delaware and headquartered in Richardson, Texas. It is listed on Nasdaq under the ticker FOSL. The company has undergone significant restructuring, including a rights offering and exchange offer in late 2025, resulting in new secured senior notes due 2029 and issuance of common stock and warrants. Fossil Group reported a wider loss in Q4 2025 with declining sales, reflecting challenges in its retail operations. The company maintains moderate liquidity with a current ratio of 1.55 as of January 3, 2026, but remains highly leveraged with substantial outstanding debt and significant interest obligations. The board and executive leadership team bring extensive experience in retail, restructuring, finance, and digital transformation. The company has an active at-the-market equity program to raise capital. Debt covenants impose restrictions on additional borrowing, dividends, and asset sales. Fossil Group faces risks related to its indebtedness, competitive retail environment, and execution of its turnaround strategy.

PSQ Holdings, Inc. is a publicly traded emerging growth company listed on the NYSE under the ticker PSQH. The company operates in the financial technology sector, focusing on payment processing and credit services through its PSQ Payments platform and Credova credit business. It reported revenues of approximately $6 million for the first half of 2024 and a net loss of $36.6 million for the full year 2025. Liquidity metrics as of December 31, 2025, show a current ratio of 2.03 and a cash ratio of 64.76, reflecting a strong liquidity position. The company experienced significant growth in Gross Merchandise Volume (GMV) processed during the 2025 Black Friday through Cyber Monday period, with PSQ Payments GMV increasing by 536% and Credova's credit business GMV increasing by 75%. The Board of Directors includes experienced individuals from finance, technology, and government sectors, with recent leadership changes including a new CFO and COO in early 2026. The company has also terminated a material asset purchase agreement due to unmet conditions. Overall, PSQ Holdings is focused on expanding its financial technology offerings while managing operational losses and leadership transitions.

AudioEye, Inc. is a publicly traded company on the Nasdaq Capital Market under the ticker AEYE. The company is incorporated in Delaware and headquartered in Tucson, Arizona. It operates with a Board of Directors comprising both executive and independent members, including CEO David Moradi who also serves as Chairman. The company reported $40.3 million in revenue and a net loss of $3.08 million for the fiscal year ended December 31, 2025. Its liquidity position as of year-end 2025 shows current liabilities exceeding current assets, with a current ratio of 0.88 and a cash ratio of 0.37. Executive compensation includes base salary, annual bonuses, and long-term equity incentives linked to performance metrics such as monthly recurring revenue and stock price. The company is classified as a smaller reporting company and is not an emerging growth company. Recent news coverage includes multiple articles on the company’s stock performance and earnings.

Splash Beverage Group, Inc. operates in the beverage sector, with a focus on branded alcoholic and non-alcoholic beverages. The company is incorporated in Nevada and headquartered in Fort Lauderdale, Florida. It is listed on the NYSE American exchange under the ticker SBEV. The company’s product portfolio includes Pulpoloco Sangria, which has recently expanded distribution through Total Wine & More. The company’s governance structure includes a five-member board with independent directors and committees overseeing audit, compensation, and governance. Financially, the company reported modest revenues but significant net losses for the fiscal year ended December 31, 2025, alongside a challenging liquidity position. The company has several loan and security agreements with outstanding obligations and related party advances. Recent management changes include the appointment of an interim CFO and director resignations. The company has received multiple buy recommendations from analysts in 2023.

Genco Shipping & Trading Limited is a global drybulk shipping company operating a fleet of 42 vessels, including Capesize, Ultramax, and Supramax classes. The company transports a variety of drybulk commodities such as iron ore, coal, grain, and steel products across international waters. Genco manages its fleet through a joint venture ship management company, consolidating its operations. The company reports financials segmented by major and minor bulk vessels, reflecting its operational focus. Genco maintains liquidity with cash and equivalents of $55.5 million and a current ratio of 2.39 as of the end of 2025. The company has experienced net losses in recent periods but continues to operate with significant equity and manageable liabilities. Corporate governance includes an experienced leadership team and recent initiatives to enhance employee retention. Genco has actively responded to takeover bids and maintains a dividend policy. The company’s financial and operational disclosures are comprehensive, providing transparency into its business model and market activities.

Catalyst Pharmaceuticals, Inc. is a Delaware-based pharmaceutical company specializing in treatments for orphan and rare diseases. The company markets products such as FIRDAPSE® and AGAMREE®, which contribute significantly to its revenues. Catalyst operates with a focus on clinical development, commercialization, and strategic acquisitions to expand its portfolio. The company maintains a strong liquidity position with substantial cash reserves and low current liabilities. Its leadership team includes experienced pharmaceutical executives, with a board comprising industry veterans. Catalyst sources active pharmaceutical ingredients and finished products from both domestic and international suppliers, including partnerships with Santhera and Eisai. The company has implemented a share repurchase program to manage capital and enhance shareholder value. Catalyst faces industry-specific risks including potential tariffs on imports and regulatory pricing policies that could impact costs and market access.

Edible Garden AG Inc operates in the sustainable agriculture and food products sector, offering branded product lines such as Pickle Party™, Pulp®, and Kick. Sports Nutrition. The company has expanded its national distribution footprint through partnerships with retailers like Safeway and PriceSmart Warehouse Clubs, and has launched products on Amazon. It has also opened a new facility in Iowa to support its strategic growth in sustainable agriculture. The company has pursued acquisitions, including NaturalShrimp assets, to strengthen its market position. Leadership includes experienced executives and a board with expertise in capital markets and food retail. The company is publicly traded on Nasdaq under ticker EDBL and maintains governance policies including a Code of Ethics and insider trading rules [N1][N3][N4][N5][N7][N8][S1].

CNS Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company incorporated in Nevada in 2017, focused on developing therapies for brain and central nervous system cancers. Its lead drug candidates are TPI 287, a third-generation taxane derivative designed to penetrate the blood-brain barrier and overcome drug resistance, and Berubicin, an anthracycline chemotherapy agent also capable of crossing the blood-brain barrier. Both drugs have received Orphan Drug Designation from the FDA, providing potential market exclusivity. TPI 287 has been studied in early-phase clinical trials across multiple cancer indications involving the CNS. Berubicin has undergone a Phase II trial comparing it to Lomustine in Glioblastoma Multiforme patients who failed first-line therapy; the trial showed comparable clinical outcomes but did not meet the primary endpoint of statistically significant overall survival improvement. The company holds exclusive licenses for its drug candidates and outsources manufacturing and sales functions. Financially, CNS Pharmaceuticals reported a net loss of approximately $15.85 million for fiscal year 2025, with cash and equivalents of $7.2 million and a current ratio near 2. The company is subject to Nasdaq listing requirements and has experienced prior compliance challenges but is currently compliant. CNS Pharmaceuticals continues to evaluate development paths for its drug candidates and plans further clinical trials subject to financing and regulatory approvals.

TuHURA Biosciences, Inc. is a clinical-stage biopharmaceutical company developing novel therapies for cancer, with a focus on immuno-oncology. Its lead candidate, IFx-2.0, targets advanced cutaneous melanoma and metastatic Merkel cell carcinoma. The company has expanded its pipeline through the acquisition of Kineta, Inc. in 2025. TuHURA's development programs are supported by regulatory designations such as FDA Orphan Drug status, and it is actively conducting clinical trials including a Phase 3 study. The company finances its operations through equity offerings and a revolving credit facility, reflecting its status as a development-stage entity with no current product revenue.

Greenlane Holdings, Inc. is a publicly traded company incorporated in Delaware and headquartered in Boca Raton, Florida. It operates through Greenlane Holdings, LLC and its subsidiaries. The company has recently shifted focus to include a digital asset treasury strategy alongside its legacy business operations. This strategy involves acquisition, lending, and trading of digital assets, including BERA tokens, under agreements with third parties. The company maintains a Board of Directors with five independent members and four standing committees, including a Digital Assets Committee to oversee digital asset activities and risk management. Key executives include CEO Jason Hitchcock, CFO Vanessa Guzmán-Clark, and CIO Benjamin Isenberg. Financially, as of December 31, 2025, Greenlane held $32.5 million in cash and equivalents, with a current ratio of 5.01, indicating strong liquidity. The company reported a net loss of $85.6 million for fiscal 2025 and modest revenue of $737,000 for Q3 2025. Greenlane faced a Nasdaq delisting notice in March 2026 due to minimum bid price non-compliance but regained compliance by April 21, 2026, maintaining its listing on the Nasdaq Capital Market. The company has related-party transactions with entities owned by executives, conducted on arm's-length terms with oversight. Executive compensation includes base salary, discretionary bonuses, and equity awards with severance provisions. The company continues to evolve its governance and operational structure to support its strategic initiatives [S1][N1][N2].

LENSAR, Inc. develops and markets ophthalmic medical devices, including the ALLY Robotic Cataract Laser System, targeting the cataract surgery market. The company is headquartered in Orlando, Florida, and is publicly traded on the Nasdaq under the ticker LNSR. Its business model centers on selling advanced laser systems and related technologies to eye care providers. Recent financial disclosures show revenue growth driven by increased system placements. The company has engaged in strategic merger discussions with Alcon Research, which were terminated in early 2026. LENSAR also provides equity-based incentives to attract and retain talent. The company maintains liquidity through cash, short-term investments, and a revolving credit facility secured by brokerage assets.

Interpace Biosciences, Inc. operates as a publicly reporting company with a structured board and executive leadership team. The company has disclosed financial results including revenue, net income, and earnings per share for recent fiscal years. It maintains equity incentive plans for executives and directors and has established compensation policies. The company has a current ratio near 2, indicating liquidity above current liabilities. Recent news coverage includes earnings performance and investor activity.